Vera Therapeutics (NASDAQ:VERA) CEO Marshall Fordyce Sells 18,500 Shares

Vera Therapeutics, Inc. (NASDAQ:VERA) CEO Marshall Fordyce sold 18,500 shares of the firm’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $35.12, for a total value of $649,720.00. Following the completion of the sale, the chief executive officer owned 235,244 shares of the company’s stock, valued at $8,261,769.28. This represents a 7.29% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Marshall Fordyce also recently made the following trade(s):

• On Tuesday, July 7th, Marshall Fordyce sold 46,250 shares of Vera Therapeutics stock. The shares were sold at an average price of $42.30, for a total transaction of $1,956,375.00.
• On Tuesday, June 23rd, Marshall Fordyce sold 18,500 shares of Vera Therapeutics stock. The shares were sold at an average price of $37.93, for a total transaction of $701,705.00.

Vera Therapeutics Stock Performance

NASDAQ:VERA opened at $35.89 on Friday. The firm has a market capitalization of $2.59 billion, a PE ratio of -6.12 and a beta of 0.96. The company has a quick ratio of 10.92, a current ratio of 10.92 and a debt-to-equity ratio of 0.18. Vera Therapeutics, Inc. has a 12-month low of $21.96 and a 12-month high of $56.05. The firm has a 50-day moving average price of $35.86 and a 200 day moving average price of $37.46.

Vera Therapeutics (NASDAQ:VERA) last released its quarterly earnings data on Monday, August 10th. The company reported ($1.52) earnings per share for the quarter, beating the consensus estimate of ($1.58) by $0.06. During the same period in the prior year, the business earned ($1.20) earnings per share. Research analysts anticipate that Vera Therapeutics, Inc. will post -6.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. Bank of America boosted their target price on shares of Vera Therapeutics from $65.00 to $70.00 and gave the company a “buy” rating in a research note on Tuesday, July 7th. TD Cowen increased their target price on shares of Vera Therapeutics from $73.00 to $78.00 and gave the stock a “buy” rating in a research report on Wednesday, July 8th. The Goldman Sachs Group reissued a “buy” rating and set a $90.00 price target on shares of Vera Therapeutics in a report on Tuesday, June 2nd. Jefferies Financial Group restated a “buy” rating and issued a $60.00 price target on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. Finally, Raymond James Financial reaffirmed a “strong-buy” rating and set a $84.00 price objective on shares of Vera Therapeutics in a research note on Tuesday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Vera Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $81.15.

Institutional Trading of Vera Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in VERA. Los Angeles Capital Management LLC bought a new position in shares of Vera Therapeutics in the fourth quarter valued at about $46,000. Aster Capital Management DIFC Ltd bought a new position in shares of Vera Therapeutics in the fourth quarter worth about $71,000. Quantbot Technologies LP acquired a new position in shares of Vera Therapeutics during the second quarter worth approximately $51,000. Nykredit A S acquired a new position in shares of Vera Therapeutics during the second quarter worth approximately $97,000. Finally, Sandia Investment Management LP bought a new stake in shares of Vera Therapeutics during the fourth quarter valued at approximately $127,000. 99.21% of the stock is currently owned by institutional investors and hedge funds.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.